rethinkPeptides Search
Menu
Study breakdown

Novel Antimicrobial Peptide Variants Found in Environmental Bacteria Show Diverse Biological Effects

evidence
The takeaway

Four novel microcin B17-like biosynthetic gene clusters from environmental Pseudomonas produced structurally similar peptide antibiotics with unexpectedly distinct physiological effects on host cells.

4 novel BGCs

Genome mining identified four new MccB17-like antimicrobial peptide gene clusters from environmental Pseudomonas

What the researchers found

Four MccB17-like BGCs from Pseudomonas produced modified peptides that caused growth retardation and cell elongation in E. coli, with transcriptomics revealing congener-specific stress responses despite structural similarity.

Why it matters

Expanding the diversity of known antibiotic peptides beyond well-studied species could yield new antimicrobial leads. The finding that similar peptides trigger different responses highlights untapped functional diversity in natural peptide antibiotics.

How the study worked

Genome mining for BGC identification, heterologous expression in E. coli, RT-qPCR and LC-MS confirmation of peptide production, overlay antimicrobial assays, and RNA-Seq transcriptome profiling.

What this study cannot tell us

No detectable antibacterial activity in standard overlay assays—the peptides' biological activity may be subtler or require different test conditions. Only expressed in E. coli as a heterologous host. Environmental relevance of these peptides is unknown.

How to read the evidence

Discovery-stage research with thorough molecular characterization. Novel findings about peptide diversity, but therapeutic application is speculative at this stage.

When this study was published

Published in 2025, advancing genome mining approaches for antimicrobial peptide discovery.

The bigger picture

This work demonstrates that genome mining of environmental bacteria can reveal novel antimicrobial peptide variants with potentially unique biological activities, expanding the toolkit for antibiotic development beyond well-characterized species.

Questions still open

  • Could these MccB17 congeners show antibacterial activity under different assay conditions or against different target bacteria?
  • What structural modifications account for the congener-specific physiological effects?
  • Can these novel peptide variants be optimized for stronger antimicrobial activity?

Common questions

What is microcin B17?
MccB17 is a natural antibiotic peptide made by E. coli bacteria. It kills other bacteria by blocking DNA gyrase, an enzyme essential for DNA replication. It belongs to a class called RiPPs (ribosomally synthesized and post-translationally modified peptides).
Why look for similar peptides in other bacteria?
Environmental bacteria have evolved diverse antimicrobial peptides over millions of years. Finding new variants of known antibiotics could reveal molecules with improved properties like broader activity spectrum or better stability.

Read the original research

Heterologous expression and functional characterization of novel microcin B17 congeners from environmental Pseudomonas isolates.

Applied microbiology and biotechnology, 110(1), 45

Citation

De Smedt, Sandrien; Wéry, Dries; Vande Capelle, Hanne; Gerstmans, Hans; Monsieurs, Pieter; Masschelein, Joleen; Ruelens, Philip; Fauvart, Maarten; Michiels, Jan. (2026). Heterologous expression and functional characterization of novel microcin B17 congeners from environmental Pseudomonas isolates.. Applied microbiology and biotechnology, 110(1), 45. https://doi.org/10.1007/s00253-025-13698-6